Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum

Abstract

BackgroundMicroRNAs (miRs) represent a distinct class of posttranscriptional modulators of gene expression with remarkable stability in sera. Several miRs are oncogenic (oncomiRs) and are deregulated in the pathogenesis of breast cancer and function to inhibit tumor suppressors. Routine blood monitoring of these circulating tumor-derived products could be of significant benefit to the diagnosis and relapse detection of early-stage breast cancer (EBC) patients.MethodsAim of this project was to determine expression of miR-155, miR-19a, miR-181b, miR-24, relative to let-7a in sera of 63 patients with EBC and 21 healthy controls. Longitudinal multivariate data analysis was performed to stochastically model the serum levels of each of the oncomiRs during disease phases: from diagnosis, after surgery, and following chemo/radiotherapy. Moreover, this analysis was utilized to evaluate oncomiR levels in EBC patients subgrouped using current clinical prognostic factors including HER2, Ki-67, and grade III.ResultsEBC patients significantly over-express the oncomiRs at the time of diagnosis. Following surgical resection the serum levels of miR-155, miR-181b, and miR-24 significantly decreased (p = 1.89e-05, 5.41e-06, and 0.00638, respectively) whereas the miR-19a decreased significantly after the therapy (p = 0.00869). Furthermore, in case of high-risk patients serum levels of miR-155, miR-19a, miR-181b, and miR-24 are significantly more abundant in comparison to low-risk group (p = 0.026, 0.02567, 0.0250, and 0.00990) and show a decreasing trend upon therapy.ConclusionsOncomiRs are significantly more abundant in the sera of EBC patients compared to controls at diagnosis. Differences in oncomiR levels reflecting EBC risk were also observed. Testing the oncomiRs may be useful for diagnostic purpose and possibly also for relapse detection in follow-up studies of EBC.

Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells

“…miRNA-155 (miR-155) is one of the miRNAs that are overexpressed in multiple cancers, as demonstrated in numerous studies (17). In gastric cancer cells, the level of miR-155 has been reported as significantly increased, and the overexpression of miR-155 promoted cell proliferation and invasion, while silencing miR-155 inhibited cell proliferation and enhanced apoptosis (18). A similar phenomenon was observed in lung cancer cells.…”

miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors

“…In silico analysis of publicly available datasets also showed that high miR-155 levels associated with poor prognosis on tamoxifen. Several studies have reported that miR-155 levels could be monitored in patients' blood samples, and that this miRNA is differentially expressed in breast cancer patients when compared with healthy women (26,51,52). Therefore, our results highlight a potential diagnostic approach and therapeutic intervention based on miR-155 patient stratification.…”

The interplay of LncRNA ANRIL and miR‐181b on the inflammation‐relevant coronary artery disease through mediating NF‐κB signalling pathway

“…Furthermore, it was mirrored that decreased miR‐181b restrained vascular remodelling by activating TGF‐β/pSmadD2/3 pathway,40 and addition of angiotensin II into cardiac fibroblasts could significantly down‐regulate miR‐181b expression 41. In addition, it has been illuminated that miR‐181b might suppress breast cancer cells’ capacity of metastasis by targeting CXCL1 and CXCL2, a couple of inflammatory cytokines 42, 43, 44. He et al45 arrived at conclusions that miR‐181b was highly expressed with prostate cancer tissues and cell line (ie.…”